Gardasil 9 HPV Vaccine Approved

Share this content:
The FDA has approved Gardasil 9 vaccine for the prevention of cervical, vulvar, vaginal, anal cancers.
The FDA has approved Gardasil 9 vaccine for the prevention of cervical, vulvar, vaginal, anal cancers.

The Food and Drug Administration (FDA) has approved Gardasil 9 (9-valent human papillomavirus types, recombinant; Merck) vaccine for the prevention of cervical, vulvar, vaginal, anal cancers, and for the prevention of genital warts caused by nine types of human papillomavirus (HPV). It is indicated for use in females 9–26 years old and males 9–15 years old.

Gardasil 9 covers five more types of HPV than the currently approved Gardasil (quadrivalent human papillomavirus types, recombinant) vaccine: HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58.

A clinical study evaluated 14,000 females ages 16–26 who were negative for vaccine HPV types at study initiation. Patients were randomized to Gardasil or Gardasil 9. Results showed Gardasil 9 was 97% effective in the prevention of cervical, vulvar, and vaginal cancers caused by the five additional HPV types (31, 33, 43, 52, and 58). Also, similar antibody responses in both groups were seen in the prevention of diseases caused by the four HPV types (6, 11, 16, 18) shared in common.

The efficacy of Gardasil 9 in females and males aged 9–15 years was established in studies that measured antibody responses to the vaccine (approximately 4,000 participants). Their antibody responses were similar to those in females ages 16–26. From these results, Gardasil 9 is predicted to have similar efficacy when administered in the younger age group.

For more information call (800) 672-6372 or visit Merck.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters